For patients managing moderate-to-severe plaque psoriasis with injectable biologics like Skyrizi (risankizumab) or Tremfya (guselkumab), the arrival of Icotyde (icotrokinra) presents a compelling oral alternative. As the first oral IL-23 receptor antagonist, Icotyde targets the same inflammatory pathway as these injectables — but in a convenient, once-daily pill. This guide walks you through why patients are making the switch, how to do it safely, and when staying on your current biologic may still be the better choice.
Why Patients Are Considering the Switch
The desire to move from injections to an oral medication is driven by several practical and personal factors:
- Injection fatigue: Repeated self-injections, even every 8–12 weeks, can become psychologically and physically draining over months and years of treatment
- Needle anxiety: Fear of needles affects a meaningful percentage of patients and can lead to missed doses or treatment non-adherence
- Lifestyle and travel convenience: Injectable biologics require cold storage and careful handling during travel. A daily pill eliminates these logistics entirely.
- Insurance or cost changes: Some plans offer better coverage or lower copays for oral agents. See our Icotyde cost and insurance guide for details.
- Injection site reactions: While generally mild, redness, swelling, or pain at injection sites can be bothersome for some patients over time
- Personal preference: Many patients simply prefer taking a daily pill as part of their morning routine over managing injection schedules
Same Pathway, Different Delivery
One of the most reassuring aspects of switching from Skyrizi or Tremfya to Icotyde is that all three medications target the IL-23 pathway — the same inflammatory signaling system driving plaque psoriasis. Skyrizi and Tremfya are monoclonal antibodies that block the p19 subunit of the IL-23 cytokine itself, while Icotyde blocks the IL-23 receptor on immune cells. The downstream effect is functionally equivalent: suppression of the Th17-driven inflammatory cascade that causes rapid skin cell turnover and plaque formation.
Because these treatments share a common mechanism, patients who have responded well to Skyrizi or Tremfya have good reason to expect a positive response to Icotyde. The switch is not a leap to an entirely different drug class — it's a change in delivery method with a closely related pharmacological target.
Washout Period Considerations
There is no mandatory washout period when transitioning from Skyrizi or Tremfya to Icotyde. Because Icotyde targets the receptor rather than the cytokine, there is no pharmacological conflict between the medications. Dermatologists typically recommend one of two approaches:
- Direct switch: Start Icotyde when the next injection dose would be due. For Skyrizi, this means beginning Icotyde 12 weeks after your last injection. For Tremfya, start 8 weeks after your last dose.
- Overlap approach: In some cases, dermatologists may start Icotyde a few weeks before the next injection is due to ensure continuous IL-23 suppression and minimize flare risk during the transition.
The best approach depends on your disease severity, current control level, and your dermatologist's clinical judgment. Never stop your injectable without first discussing timing with your provider.
Compare telehealth providers for your condition
MedSwitcher helps you compare vetted online providers, understand costs, and find the right treatment.
Browse All Guides →What to Expect During the Transition
Most patients experience a smooth transition from injectable to oral therapy. Icotyde begins working within 4–8 weeks, with peak effects typically seen by week 16. During this period, patients should:
- Monitor for flares: A temporary increase in symptoms is possible as the injectable wears off and Icotyde builds to therapeutic levels. Keep topical corticosteroids on hand as a bridge.
- Track symptoms: Maintain a symptom journal noting skin clearance, any new plaques, and how you feel overall. This helps your dermatologist assess the transition.
- Schedule follow-ups: Plan dermatology appointments at 4, 8, and 16 weeks after starting Icotyde to evaluate response and adjust treatment if needed.
- Expect mild GI effects: Some patients experience transient nausea or diarrhea when starting Icotyde. These typically resolve within 2–4 weeks.
Efficacy: How Does Icotyde Compare?
Injectable IL-23 inhibitors currently hold a slight edge in peak efficacy. In clinical trials, Skyrizi achieved ~75–80% IGA 0/1 at week 24, while Tremfya reached ~70% IGA 0/1. Icotyde, in the ICONIC trial, demonstrated 74% IGA 0/1 at week 24 — a highly competitive result that falls squarely between the two injectable benchmarks.
| Metric | Icotyde | Skyrizi | Tremfya |
|---|---|---|---|
| IGA 0/1 (Wk 16) | ~70% | ~75% | ~65% |
| IGA 0/1 (Wk 24) | 74% | ~78% | ~70% |
| PASI 90 (Wk 16) | ~55% | ~70–73% | ~65% |
| Route | Oral daily | Injection q12wk | Injection q8wk |
For most patients, the difference in efficacy is clinically modest and may be outweighed by the convenience, adherence, and quality-of-life benefits of oral therapy. For a deeper comparison including Otezla and Sotyktu, see our full treatment comparison guide.
When Switching Makes Sense
Switching from Skyrizi or Tremfya to Icotyde is a reasonable choice if you:
- Are well-controlled on your current injectable but want a more convenient option
- Experience injection site reactions or significant needle anxiety
- Travel frequently and find cold-chain storage burdensome
- Face insurance or cost barriers with injectable biologics
- Want a daily pill that fits naturally into your routine
When to Stay on Your Current Biologic
Staying on Skyrizi or Tremfya may be the better choice if:
- You have severe psoriasis that requires maximum possible clearance and are achieving excellent results on your current injectable
- You have psoriatic arthritis, where injectable biologics have stronger evidence for joint protection and structural damage prevention
- You prefer the simplicity of an injection every 8–12 weeks over remembering a daily pill
- Your insurance covers your current biologic well and Icotyde would require new prior authorization or step therapy
- You've tried and failed oral psoriasis medications in the past
The guiding principle is simple: if your current treatment is working well and you're comfortable with it, there's no medical imperative to switch. But if injection burden, cost, or convenience are affecting your quality of life or adherence, Icotyde is the strongest oral alternative available in 2026.
The Bottom Line
Switching from Skyrizi or Tremfya to Icotyde is a safe, well-supported transition for many psoriasis patients. The shared IL-23 pathway, competitive efficacy data, and clean safety profile make Icotyde a legitimate oral alternative to injectable biologics. Discuss your goals, disease severity, and insurance situation with your dermatologist to determine whether the switch is right for you. For comprehensive background on Icotyde itself, visit our complete Icotyde guide.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your dermatologist or healthcare provider before making changes to your treatment plan.